Session: SUN 624-646-Growth: Clinical Trials & Observational Studies
Poster Board SUN-633
Method and Results: Of 195 NS and 1070 TS patients, 22 NS patients (18 males, 4 females) and 255 female TS patients with complete 4-year longitudinal data were included in repeated measures regression analysis. At baseline, NS and TS patients did not differ significantly (mean±SD) in age (NS: 8.8±3.5 yrs; TS: 7.9±3.2 yrs), HSDS (NS: -2.72±0.92; TS: -2.67±0.88), bone age (NS: 7.30±3.65 yrs; TS: 6.73±2.94 yrs) or corrected HSDS (NS: -2.29±1.13; TS: -2.46±1.08). IGF-I SDS was lower in NS (-1.36±1.22) than TS patients (‑0.89±1.52), but this was also not significant. At Y1 and Y2, mean changes in HSDS (DHSDS) from baseline in NS and TS patients were similar (Y1, NS: +0.50, TS: +0.52, P=0.86; Y2, NS: +0.87, TS: +0.82, P=0.72), but diverged after Y3 with a trend towards greater ΔHSDS observed in NS patients (Y3, NS: +1.13, TS: +0.96, P=0.24; Y4, NS: +1.28, TS: +1.03, P=0.11). A trend towards greater corrected DHSDS in Y4 from baseline in NS patients was also observed (NS: +1.26, TS: +1.02; P=0.13).
The mean GH dose over 4 years was similar between patients with NS (49 mcg/kg/day) and TS (48 mcg/kg/day), but a slight decrease in GH dose was observed in TS patients compared to baseline (P=0.02). A negative correlation between DHSDS and baseline age was observed over the first 3 years of GH treatment in NS patients; in TS patients, a negative correlation between DHSDS and age was present at all 4 years.
Conclusions: NS and TS patients responded similarly in mean DHSDS and corrected HSDS over 4 years of GH treatment with greater than +1 SDS gain. The trend towards greater increases in HSDS and corrected HSDS in NS patients may be due to the effect of puberty in NS patients and the decrease in GH dose over time in TS patients. The negative correlation between DHSDS and age for both NS and TS patients highlights the importance of early initiation of GH treatment.
Disclosure: PAL: Research Funding, Ipsen, Research Funding, Eli Lilly & Company, Research Funding, Abbott Laboratories, Consultant, Novo Nordisk, Consultant, Ipsen, Consultant, Abbott Laboratories, Research Funding, Novo Nordisk. JLR: Research Funding, Pfizer, Inc., Research Funding, Novo Nordisk, Research Funding, Eli Lilly & Company, Consultant, Novo Nordisk, Consultant, Eli Lilly & Company, Consultant, Abbott Laboratories. IMO: Study Investigator, Novo Nordisk. BT: Employee, Novo Nordisk. JAG: Employee, Novo Nordisk. HTC: Study Investigator, Novo Nordisk.
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters